vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened

Key Points

• vTv Therapeutics shares fell below their 50-day moving average, trading as low as $31.07 versus the $32.37 average, and last changing hands at $31.10 on volume of 11,170 shares.
• Analyst sentiment remains mixed, but the stock carries a consensus “Moderate Buy” rating with an average price target of $55.83, compared with recent trading near $31.
• The biotechnology company reported a quarterly loss of $1.05 per share, missing estimates by $0.08; analysts expect a full-year loss of approximately $2.35 per share.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $32.37 and traded as low as $31.07. vTv Therapeutics shares last traded at $31.10, with a volume of 11,170 shares.

Analyst Ratings Changes

VTVT has been the subject of several analyst reports. Weiss Ratings cut shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Lifesci Capital upgraded shares of vTv Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 2nd. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a "buy" rating and a $67.00 price objective for the company. Wall Street Zen lowered shares of vTv Therapeutics from a "buy" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Zacks Research raised vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $55.83.

vTv Therapeutics Price Performance

The company has a market cap of $122.53 million, a PE ratio of -29.34 and a beta of 0.29. The business has a 50 day moving average of $32.37 and a 200 day moving average of $34.14.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). Sell-side analysts forecast that vTv Therapeutics Inc. will post -2.35 EPS for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company's research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.